{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:08:24Z","timestamp":1785874104800,"version":"3.56.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"Importance<\/jats:title>Psoriasis in children is increasingly treated with systemic medications, yet their risk of serious infection is not well characterized in clinical practice. Pediatric clinical trials for these medications were often small and placebo controlled.<\/jats:p><\/jats:sec>Objective<\/jats:title>To estimate the 6-month rate of infections among children with psoriasis who started treatment with ustekinumab, etanercept, or methotrexate.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study used insurance claims data from clinical practices across the US on children aged 17 years or younger with psoriasis who were receiving treatment with a topical medication for psoriasis and started new treatment with ustekinumab, etanercept, or methotrexate. The analysis was stratified by the time before pediatric labeling (2009-2015) and after pediatric approval (2016-2021). Patient follow-up started 1 day after initiating treatment and ended at 6 months.<\/jats:p><\/jats:sec>Exposures<\/jats:title>New treatment with ustekinumab, etanercept, and methotrexate.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>During follow-up, the frequency of inpatient serious infections and outpatient infections requiring treatment was compared. Event rates and rate ratios were estimated after propensity score decile stratification.<\/jats:p><\/jats:sec>Results<\/jats:title>After exclusions, we identified 2338 patients (1368 girls [57.8%]) who initiated new treatment with a targeted immunomodulating agent. In all, 379 patients started treatment with ustekinumab, 779 patients started treatment with etanercept, and 1180 patients started treatment with methotrexate from 2009 through 2021. The propensity score\u2013adjusted incidence rate of serious infection was 18.4 per 1000 person-years (3 events) for ustekinumab users, 25.6 per 1000 person-years (9 events) for etanercept users, and 14.9 per 1000 person-years (8 events) for methotrexate users. The adjusted rate of outpatient infections was 254.9 per 1000 person-years (39 events) for ustekinumab users, 435.7 per 1000 person-years (139 events) for etanercept users, and 433.6 per 1000 person-years (209 events) for methotrexate users. The adjusted rate ratio of outpatient infections was 0.58 (95% CI, 0.41-0.83) for ustekinumab vs etanercept, 0.66 (95% CI, 0.48-0.91) for ustekinumab vs methotrexate, and 0.95 (95% CI, 0.75-1.21) for etanercept vs methotrexate. Rate ratios were similar during the off-label use era and after pediatric labeling.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Among children with psoriasis who started treatment with immunomodulating agents, serious infections were infrequent. This cohort study suggests that there was no increase in the risk of outpatient infections for children who started treatment with ustekinumab compared with etanercept or methotrexate.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2022.6325","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T16:05:03Z","timestamp":1675872303000},"page":"289","source":"Crossref","is-referenced-by-count":11,"title":["Risk of Infection in Children With Psoriasis Receiving Treatment With Ustekinumab, Etanercept, or Methotrexate Before and After Labeling Expansion"],"prefix":"10.1001","volume":"159","author":[{"given":"Maria C.","family":"Schneeweiss","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Savage","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Infectious Disease, Boston Children\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wyss","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhu","family":"Jin","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Schoder","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Rheumatology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sidbury","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Pediatrics, Seattle Children\u2019s Hospital, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Oduol","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Glynn","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"doi220071r1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1001\/jamadermatol.2017.5417","article-title":"Association of psoriasis with comorbidity development in children with psoriasis.","volume":"154","author":"Tollefson","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"3","key":"doi220071r2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40272-021-00443-5","article-title":"Targeted therapy for pediatric psoriasis.","volume":"23","author":"Nogueira","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"12","key":"doi220071r3","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archderm.141.12.1537","article-title":"Prevalence and treatment of psoriasis in the United Kingdom: a population-based study.","volume":"141","author":"Gelfand","year":"2005","journal-title":"Arch Dermatol"},{"issue":"6","key":"doi220071r4","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/pde.2011.28.issue-6","article-title":"The burden of childhood psoriasis.","volume":"28","author":"De Jager","year":"2011","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"doi220071r5","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jaad.2009.07.029","article-title":"Incidence of psoriasis in children: a population-based study.","volume":"62","author":"Tollefson","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi220071r6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"doi220071r7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9812","article-title":"FDA approved biologics: can etanercept and ustekinumab be considered a first-line systemic therapy for pediatric\/adolescents in moderate to severe psoriasis? a systematic review.","volume":"12","author":"Aslam","year":"2020","journal-title":"Cureus"},{"issue":"3","key":"doi220071r8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis.","volume":"358","author":"Paller","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"doi220071r9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.","volume":"73","author":"Landells","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi220071r10","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/bjd.v183.4","article-title":"Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (=6 to <12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study.","volume":"183","author":"Philipp","year":"2020","journal-title":"Br J Dermatol"},{"issue":"8","key":"doi220071r11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/pds.3447","article-title":"Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009.","volume":"22","author":"Asgari","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4S","key":"doi220071r12","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jaci.2017.01.009","article-title":"Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines.","volume":"139","author":"Eichenfield","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"doi220071r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pds.v22.1","article-title":"The incident user design in comparative effectiveness research.","volume":"22","author":"Johnson","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"doi220071r14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/M18-3079","article-title":"Graphical depiction of longitudinal study designs in health care databases.","volume":"170","author":"Schneeweiss","year":"2019","journal-title":"Ann Intern Med"},{"issue":"4","key":"doi220071r15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jclinepi.2006.07.011","article-title":"Veteran\u2019s Affairs hospital discharge databases coded serious bacterial infections accurately.","volume":"60","author":"Schneeweiss","year":"2007","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"doi220071r16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020857","article-title":"Validation of discharge diagnosis codes to identify serious infections among middle age and older adults.","volume":"8","author":"Wiese","year":"2018","journal-title":"BMJ Open"},{"issue":"7","key":"doi220071r17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/pds.v25.7","article-title":"Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database.","volume":"25","author":"Sahli","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"doi220071r18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.annepidem.2014.05.011","article-title":"Positive predictive value of primary inpatient discharge diagnoses of infection among cancer patients in the Danish National Registry of Patients.","volume":"24","author":"Holland-Bill","year":"2014","journal-title":"Ann Epidemiol"},{"issue":"9","key":"doi220071r19","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","article-title":"Association between biologics use and risk of serious infection in patients with psoriasis.","volume":"157","author":"Penso","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi220071r20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.cgh.2020.12.030","article-title":"Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease.","volume":"20","author":"Kirchgesner","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"doi220071r21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/aje\/kwaa244","article-title":"Development and validation of a pediatric comorbidity index.","volume":"190","author":"Sun","year":"2021","journal-title":"Am J Epidemiol"},{"issue":"12","key":"doi220071r22","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models.","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"doi220071r23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects.","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"2","key":"doi220071r24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","article-title":"A propensity-score\u2013based fine stratification approach for confounding adjustment when exposure is infrequent.","volume":"28","author":"Desai","year":"2017","journal-title":"Epidemiology"},{"issue":"3","key":"doi220071r25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/aje\/kwy263","article-title":"Multinomial extension of propensity score trimming methods: a simulation study.","volume":"188","author":"Yoshida","year":"2019","journal-title":"Am J Epidemiol"},{"issue":"10","key":"doi220071r27","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects.","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med"},{"issue":"25","key":"doi220071r28","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"3","key":"doi220071r29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cpt.v99.3","article-title":"Transparency and reproducibility of observational cohort studies using large healthcare databases.","volume":"99","author":"Wang","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"doi220071r30","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/art.v69.6","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study.","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"doi220071r31","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.2337\/dc19-0069","article-title":"Using real-world data to predict findings of an ongoing phase IV cardiovascular outcome trial: cardiovascular safety of linagliptin versus glimepiride.","volume":"42","author":"Patorno","year":"2019","journal-title":"Diabetes Care"},{"issue":"10089","key":"doi220071r33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"doi220071r34","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3109\/09546634.2014.996515","article-title":"Methotrexate in pediatric plaque-type psoriasis: long-term daily clinical practice results from the Child-CAPTURE registry.","volume":"26","author":"van Geel","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"doi220071r35","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jaad.2020.02.065","article-title":"Serious infection risk in children with psoriasis on systemic treatment: a propensity score\u2013matched population-based study.","volume":"82","author":"Schneeweiss","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"23","key":"doi220071r36","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"doi220071r37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40264-016-0480-3","article-title":"Propensity score weighting compared to matching in a study of dabigatran and warfarin.","volume":"40","author":"Seeger","year":"2017","journal-title":"Drug Saf"},{"issue":"12","key":"doi220071r38","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1177\/0962280220940334","article-title":"Propensity score weighting under limited overlap and model misspecification.","volume":"29","author":"Zhou","year":"2020","journal-title":"Stat Methods Med Res"},{"issue":"7","key":"doi220071r39","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/aje\/kwq198","article-title":"Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution\u2014a simulation study.","volume":"172","author":"St\u00fcrmer","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"6","key":"doi220071r40","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","article-title":"Relaxing the rule of ten events per variable in logistic and Cox regression.","volume":"165","author":"Vittinghoff","year":"2007","journal-title":"Am J Epidemiol"},{"key":"doi220071r26","volume-title":"Modern Epidemiology","author":"Rothman","year":"2021"},{"key":"doi220071r32","unstructured":"Aetion. Aetion Evidence Platform: software for real-world data analysis. Accessed December 28, 2022. https:\/\/aetion.com\/technology\/platform\/"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2800955\/jamadermatology_schneeweiss_2023_oi_220071_1677862982.1741.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T15:13:20Z","timestamp":1678893200000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2800955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.6325","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}